HNSBF News and Press, Hansa Biopharma AB

2024-07-18 13:17:06 ET Hansa Biopharma AB (publ) (HNSBF) Q2 2024 Results Conference Call July 18, 2024 08:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Hitto Kaufmann - Chief...

2024-07-18 12:49:30 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma Read the full article on Seeking Alpha For further details see: Hansa Biopharma Q2 GAAP EPS of -SEK3.30

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting PR Newswire LUND , Sweden , May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be present...

2024-04-18 14:22:55 ET More on Hansa Biopharma Hansa Biopharma AB (publ) 2024 Q1 - Results - Earnings Call Presentation Hansa Biopharma AB (publ) (HNSBF) Q1 2024 Earnings Call Transcript Hansa Biopharma AB (publ) 2023 Q4 - Results - Earnings Call Presentation ...

2024-04-18 11:45:23 ET Hansa Biopharma AB (publ). (HCHDF) Q1 2024 Earnings Conference Call April 18, 2024, 08:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Hitto Kaufmann - C...

2024-04-02 10:17:06 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma Read the full article on Seeking Alpha For further details see: Hansa Biopharma expects to report revenue of about SEK 54...

2024-02-02 14:30:04 ET Hansa Biopharma AB (publ) (HNSBF) Q4 2023 Earnings Conference Call February 02, 2024 8:00 AM ET Company Participants Søren Tulstrup – Chief Executive Officer Matt Shaulis – Chief Commercial Officer and U.S. President Hitt...

2024-02-02 03:15:55 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma Read the full article on Seeking Alpha For further details see: Hansa Biopharma GAAP EPS of -SEK2.40, revenue of SEK50.4M

2024-01-08 10:42:44 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma For further details see: Hansa Biopharma expects to report Q4 total revenue of SEK 50M

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...